Abstracts tagged "adverse events and rheumatoid arthritis (RA)"

Abstract Number: 269 • 2018 ACR/ARHP Annual Meeting
Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials
Katie Tuckwell, Edmond Teng, Jenny Chia, Daisy Lee, Joshua Galanter, Jodie Peake and Daniel Keebler, Genentech, Inc., South San Francisco, CA
Background/Purpose: Clinical trials are becoming increasingly globalized, with more representation from Asia, Latin America, and the Russian Federation and Eastern Europe (RFEE).1 Adverse event (AE)…
Abstract Number: 1541 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Yukihiko Ikeda¹, Ryo Rokutanda¹, Sho Fukui¹, Haruki Sawada², Mitsuru Watanabe³, Ayako Koido³, Yuko Kataoka¹, Rui Kawato⁴, Haruyuki Yanaoka⁵, Masei Suda⁶, Yuri Ohara⁷, Hiromichi Tamaki¹, Hisanori Shimizu⁶, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ⁷Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
The retention rate and safty profile of iguratimod in real clinical practice: Analysis of 456 patients with Rheumatoid arthritis. Abstract Background/Purpose: Iguratimod is one of…
Abstract Number: 15 • 2016 ACR/ARHP Annual Meeting
Adverse Events and Persistency of Biologics in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Dam Kim¹, Soo-Kyung Cho², Soyoung Won³, Hoon-Suk Cha⁴, Chan-Bum Choi⁵, Seung-Jae Hong⁶, Jisoo Lee⁷, Dong-Hyuk Sheen⁸, Dae-Hyun Yoo⁹, Sang-Cheol Bae¹⁰ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Dept. of Rheumatology, #1 Hoeg, KyungHee University Medical Center, SEOUL, South Korea, ⁷Int Medicine, Ewha Woman's Univ Schl of Med, Seoul, Korea, Republic of, ⁸Division of Rheumatology, Eulji University, Daejeon, Korea, The Republic of, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, The Republic of
Background/Purpose: RA associated ILD (RA-ILD) is reported as 1-58% depending on the study population and the definition of ILD, and RA-ILD is known to be…
Abstract Number: 2367 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Luis Rodriguez-Rodriguez¹, Leticia Leon², Zulema Rosales², Cristina Lajas², Lucía Arietti², Ana B. Rodríguez-Cambrón², Cristina Martínez-Prada², Jose María Leal², Pilar Macarrón², Gloria Candelas², Juan A. Jover² and Lydia Abásolo², ¹Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…
Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].